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Review Article
A Review on Differences in Effects on
Normal and Malignant Cells and Tissues
to Electroporation-Based Therapies:
A Focus on Calcium Electroporation
Stine K Frandsen, MSc, PhD1 and Julie Gehl, Prof. MD1,2
Abstract
Calcium electroporation is a potential novel anticancer treatment, where high concentrations of calcium are introduced into the
cell cytosol by electroporation. This is a method where short, high-voltage pulses induce a transient permeabilization of the cell
membrane and thereby allow influx and efflux of ions and molecules. Electroporation is used in combination with chemother-
apeutic drugs (electrochemotherapy) as a standard treatment for cutaneous metastases, and electroporation using a higher
electric field and number of pulses (irreversible electroporation) is increasingly being used as an anticancer treatment. In this
review, calcium electroporation is described with emphasis on the investigations of differences in the effect on normal and
malignant cells and tissues in vitro and in vivo. Calcium electroporation has been shown to induce cell death in vitro and tumor
necrosis in vivo with a difference in sensitivity between different tumor types. Normal cells treated in vitro are significantly less
affected than cancer cells, and a similar trend is shown in vivo where muscle and skin tissue surrounding a treated tumor as well as
muscle and skin directly treated with calcium electroporation were less affected than tumors. The mechanism behind this dif-
ference in sensitivity is not fully understood but might be affected by differences in electric impedance, membrane repair, and
expression of plasma membrane calcium ATPases in normal and malignant cells. The research on calcium electroporation shows a
potential novel anticancer treatment with significant effect on cancer cells and tissues while normal cells and tissues are clearly less
affected.
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Introduction
Electroporation is a method where short, high-voltage pulses
induce a transient permeabilization of the cell membrane,
allowing passage of ions and molecules into and out of the
cell.1 Permeabilization is induced when the applied electric
field leads to an increase in the transmembrane potential that
surpasses the threshold for permeabilization, leading to the
formation of aqueous pores.2 This permeabilization is reversi-
ble (reversible electroporation), and the method is used in com-
bination with chemotherapeutic drugs (electrochemotherapy
[ECT]) for treatment of cutaneous and subcutaneous
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metastases3-13 and is in clinical trial for treatment of tumors in
internal organs.14,15 Electroporation has also been proposed to
be used as a monotherapy (ie, without combining with che-
motherapeutic or other drugs) for destruction of the cell mem-
brane and thereby induce cell death.16 This is named
irreversible electroporation (IRE) and is performed by using
a far higher electric field and higher number of pulses than that
used for reversible electroporation. Recently, a potential novel
anticancer treatment was proposed by combining reversible
electroporation and calcium (calcium electroporation
[CaEP]).17 Results from the first clinical trial using CaEP for
treatment of cutaneous metastases were recently published and
showed a clear effect of CaEP comparable to the effect of
ECT.18 The mechanism behind CaEP is still being elucidated,
but interestingly differences in sensitivity between normal and
malignant cells have been observed.
When testing new anticancer treatments, the effect on tumor
cells as well as normal cells is crucial to investigate. Electro-
chemotherapy, IRE, and CaEP are local treatments, thus the
normal tissue mostly affected is surrounding the treated tumor.
In this review, we briefly describe the effects of ECT and IRE
on normal cells and tissues followed by a description of the
literature on differences in effects between malignant and nor-
mal cells and tissues after treatment with CaEP.
Electrochemotherapy
The first clinical trial with ECT was performed in 1990 to
199119 and has since been tested in several clinical trials for
treatment of cutaneous and subcutaneous metastases3,4,7-13 as
well as for tumors in internal organs.14,15 Electrochemotherapy
is now in clinical use in more than 140 centers in Europe. The
most commonly used chemotherapeutic drugs for ECT are
bleomycin and cisplatin, and their cytotoxicity has been shown
to increase 300 to 5000-fold and 2 to 13-fold, respectively,
when combined with electroporation.1 It has been shown that
ECT using bleomycin affects normal cells less than cancer cells
in vitro in cells in suspension20 and in spheroids, a 3D tumor-
like structure,21 which might be due to the effect of bleomycin
on fast dividing cells compared to more quiescent cells, such as
fibroblasts. In patients, the surrounding normal tissue is also
less affected than the treated tumor, when the treatment also
included normal tissue around the tumor.22 In a recent study, it
was shown that the functionality of larger normal vessels was
preserved while the tumor tissue was necrotic after ECT of
liver metastases.23 Furthermore, tumor blood vessels have also
been shown to be more affected than normal blood vessels.24 A
factor contributing to the difference in sensitivity between nor-
mal and cancer cells is likely the increased effect of chemother-
apeutic drugs on fast dividing cells.25 Another reason might be
how the electric field influences specific cells and tissues. This
could be differences in the electrical impedance of the tissues,
where normal liver tissue has been shown to have higher impe-
dance and thereby lower conductivity than cancerous liver tis-
sue.26 Difference in membrane repair in vitro has also been
shown between normal and cancer cells where normal cells
repair faster than cancer cells which indicates that normal cells
are permeabilized for a shorter period than cancer cells after
electroporation.27 These differences in the effect of electro-
poration between normal and cancer cells might influence the
effect of ECT, CaEP, and IRE as described subsequently and
summarized in Table 1.
Irreversible Electroporation
Electroporation without the addition of a chemotherapeutic
drug is investigated as an anticancer treatment.16 In IRE, a
higher number of pulses as well as a higher electric field are
applied to the cells causing a permanent permeabilization of the
cell membrane and thereby cell death. Irreversible electropora-
tion has been shown to effectively inhibit proliferation in dif-
ferent cancer cells in vitro, both cells in suspension and 3D
cultured cells.28-30 In vivo, IRE also induces tumor cell death
which has been shown on tumors implanted on mice.31,32
Recently, high-frequency IRE has also been shown to be effec-
tive for hepatic ablation in a porcine model.33,34 The first clin-
ical trial using IRE was performed on tumors in the kidney,35
and several studies have followed describing treatment of
tumors in internal organs such as liver, lung, and pancreas as
a treatment that seems safe and feasible.36-38 Irreversible elec-
troporation has been shown to be used for tissue destruction,
and normal tissue seems to also be affected.37,39 In a study on
mice using a dorsal skinfold chamber, reduced blood perfusion
was shown after IRE32; however, in a clinical trial where
patients with hepatic cancer were treated with IRE, the venous
structure adjacent to the treated area remained largely unaf-
fected by the treatment.40 In a recent study, it was shown that
nerves adjacent to tumors on rabbits treated with IRE were
severely damaged, but their function and structure returned to
normal in a few weeks.41 But in a canine sarcoma tumor treated
with IRE, the tumor tissue was clearly affected while the adja-
cent nerves and muscle tissue were spared.42 In the studies
where differences between normal and malignant cells have
been observed, it might be due to differences in the electrical
impedance of the different tissues and/or differences in mem-
brane repair as described earlier (Table 1).
Table 1. Contributing Factors for Difference in Sensitivity Between
Normal and Malignant Tissues.a
ECT IRE CaEP Reference
Electrical impedance þ þ þ 26
Membrane repair þ ? þ 27
Vascular effect þ þ ? 24,32,40
Drug cytotoxicity þ NA þ 25,52
Drug removal ? NA þ 52
aReasons that could influence the observed differences in sensitivity of ECT,
IRE, and CaEP between normal and malignant cells/tissues. þ indicates that
the treatment is likely affected and ? indicates that this has not been investi-
gated for the specific treatment.
Abbreviation: NA, not applicable.
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CaEP: Difference in Effect of Normal and
Malignant Cells and Tissues
Calcium electroporation was described as a potential novel
anticancer treatment in 2012.17 The treatment was shown to
effectively induce cell death in vitro and tumor necrosis in vivo.
Further studies have shown a similar effect of CaEP and ECT
using bleomycin in vitro.43,44 The first clinical trial was
recently conducted, where cutaneous metastases were rando-
mized to treatment with CaEP or ECT using bleomycin, show-
ing a comparable effect between the 2 treatments.18 The
mechanism behind CaEP is likely complex, but it has been
shown to be associated with adenosine triphosphate (ATP)
depletion in vitro and in vivo,17,45-47 which might be due to
direct loss of ATP through the permeabilized membrane,48
increased consumption of ATP by the Ca2þ-ATPases to trans-
port calcium out of the cells,49 and reduced production of ATP
due to disruption in the mitochondrial membrane potential by
the high intracellular calcium concentrations.50 The high cal-
cium concentration might also cause generation of reactive
oxygen species (ROS) and activation of lipases and
proteases.51
Several cancer cells have been tested in vitro, showing a
clear dose–response but with a difference in sensitivity to
CaEP.17,43,44,47 This difference has been confirmed in vivo,
where 4 different tumor types (bladder, breast, colon, and
small-cell lung cancer), injected or transplanted subcuta-
neously on immune-incompetent mice, have been treated with
CaEP.17,52 The difference in sensitivity could be caused by the
difference in electroporation effects (described above) as well
as differences in the cellular response to increased calcium
concentrations, but further research is needed, in vitro and
in vivo as well as in the clinical setting. The effect of CaEP
has also been investigated on normal cells and tissues. Inter-
estingly, in 2 recent studies, normal rat and mouse skeletal
muscle cells treated as cells in suspension were notably less
affected by CaEP than the tested murine fibrosarcoma and
human rhabdomyosarcoma cells, respectively.44,53 But in pri-
mary normal human dermal fibroblasts, no difference in viabi-
lity was observed between the normal cells and 3 cancer cell
lines when treated as cells in suspension.45 As described ear-
lier, fibroblasts are more quiescent cells than cancer cells, and
this could affect their sensitivity to treatment, but this is not
seen in vitro on cells in suspension. However, when treated as
cells in spheroids, a clear difference was observed. Normal
fibroblasts were grown in spheroids, a 3D in vitro structure,
and treated with similar conditions as in vivo. The size of the
spheroids (1 normal and 3 malignant) was determined at days 2,
3, and 4 after treatment as a measure of treatment effect. All the
malignant spheroids decreased in size after treatment with
CaEP, similar to spheroids treated with ECT using bleomycin,
while the normal cell spheroids treated with CaEP or ECT did
not decrease in size compared to untreated spheroids (Figure
1). This showed a clear difference in effect between normal and
malignant cells when treated as spheroids which are an in vitro
model closer to the in vivo setting than cells in suspension.
Interestingly, the ATP level decreased significantly in all the
spheroids, normal and malignant, showing that the normal cells
are able to survive this loss of ATP.46
The effect of CaEP in vivo on normal tissue surrounding a
treated tumor was investigated.52 Human breast cancer tumors
on mice were treated with CaEP using different concentrations
of calcium, and 2 days after treatment, tumors as well as the
muscle below and the skin above the treated tumors were
removed, and the effect on the different tissues was estimated
by histological analyses. In the tumors, the fraction of necrosis
increased significantly after treatment with CaEP, independent
of the calcium concentration used. In the surrounding normal
tissue, the effect was less pronounced. In 80% of the muscle
samples located below the treated tumors, no necrosis was
observed. In the skin tissue located above the treated tumor,
inflammation, extravasation of erythrocytes, and edema were
observed but to the same degree as in skin samples located
Figure 1. The effect of calcium electroporation (CaEP) on normal and cancer cell spheroids. In a spheroid study, colon cancer cell spheroids and
normal dermal fibroblast spheroids were treated with CaEP. No decrease in spheroid size or viability was seen in normal cell spheroids, while a
significant decrease in size and viability was observed in the colon cancer spheroids. The spheroids were treated 5 days after seeding the cells
and due to differences in doubling time the size of the spheroids differs at treatment time. Adapted from Frandsen, Gibot et al, 2015.46
Frandsen and Gehl 3
above untreated tumors, indicating that the presence of the
tumor caused the changes and not the CaEP treatment. In the
same study, normal muscle and skin tissues were also directly
treated with CaEP. In these muscle samples, only 40% of the
samples showed no necrosis; however, when looking at
the fraction of necrosis in the muscle samples, only 10% of the
muscle tissue was necrotic; thus, most of the muscle samples
showed some necrosis but it was only in a small part of each
muscle sample. This fraction was much lower than that in the
tumors treated with CaEP. In the skin tissue directly treated, no
edema was seen, and a limited degree of inflammatory markers
were present in the treated samples however to the same degree
as was observed in control samples. Overall, this study shows a
clear difference between normal and malignant tissues treated
with CaEP.52
In the clinical trial comparing CaEP and ECT using bleo-
mycin, the effect on the surrounding normal tissue was not
directly investigated, but no damage on normal structures was
reported.18 Investigations on the effect on normal tissue in
patients may be added to future studies.
As described earlier, the mechanism behind CaEP is not
yet fully understood. Thus, the reason for the observed differ-
ences between normal and malignant cells and tissues treated
with CaEP is not completely known. However, a few differ-
ences between normal and malignant cells in relation to CaEP
sensitivity have been shown. The different effects of electro-
poration on normal and malignant cells, described earlier, will
likely also influence the overall effect of CaEP and therefore
be part of the reason for the observed difference in sensitivity
(Table 1). In a recent in vivo study,52 the intracellular calcium
content was measured before and after treatment with CaEP.
The calcium content was measured in tumor as well as the
muscle below and the skin above the treated tumor. In the
tumor tissue, intracellular calcium content increased signifi-
cantly and was still significantly higher 4 hours after treat-
ment than in untreated tumor tissue. Interestingly,
intracellular calcium content was significantly higher in the
skin tissue above tumors treated with CaEP 15 minutes and
60 minutes after treatment than in untreated skin, but the
calcium content decreased 4 hours after treatment to a level
comparable with the calcium content in untreated skin tissue.
In the muscle tissue, no significant changes in intracellular
calcium content were observed. These results indicate that the
skin tissue is able to reestablish the intracellular calcium con-
tent unlike the tumor tissue. In the same study,52 the expres-
sion of the plasma membrane calcium ATPase (PMCA) in
vitro was measured, showing a significantly lower expression
of total PMCA in the tested cancer cell lines compared to
normal dermal fibroblasts. In a recent study, it was shown
that CaEP caused a decreased expression of PMCA as well
as the sodium calcium exchanger (NCX1) in malignant mus-
cle cells but not in normal muscle cells.53 In this study, it was
also shown that CaEP affects the cytoskeleton structure more
in malignant cells than in normal cells.53 Thus, normal cells
might have a higher capability of pumping calcium out the
cell as well as keeping normal cell structure compared to
cancer cells and thereby reestablish intracellular calcium con-
centration and increase survival.
Conclusion and Perspectives
Since the first article on CaEP as a potential novel anticancer
treatment was published, several papers have followed show-
ing a clear anticancer effect in vitro, in vivo, and in the clinical
setting. Furthermore, normal and malignant cells and tissues
show different sensitivity to CaEP with normal cells being less
affected than cancer cells. The mechanism behind this differ-
ence in sensitivity is not yet fully understood but might be
influenced by differences in the response to the electroporation
procedure between cell types, and differences in cytoskeleton
structure after treatment as well as differences in the cellular
capacity to handle increased intracellular calcium concentra-
tions, such as differences in the PMCA and NCX1 expression.
Further investigations are needed to understand the mechanism
behind CaEP and thereby the differences in sensitivity between
normal and malignant cells and tissues.
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